Today: 7 February 2026
Subscribe
Browse Category

Healthcare Industry News 23 December 2025 - 5 January 2026

Eli Lilly stock slides as Novo’s Wegovy pill hits U.S. shelves and stokes obesity-drug pricing fears

Eli Lilly stock slides as Novo’s Wegovy pill hits U.S. shelves and stokes obesity-drug pricing fears

New York, January 5, 2026, 10:58 (ET) — Regular session Eli Lilly and Company shares fell about 3.4% on Monday, extending early losses after rival Novo Nordisk began selling a pill version of its Wegovy weight-loss drug in the United States. The stock was down at $1,043.14 after dipping nearly 4% earlier in the session. The move puts the spotlight back on pricing power in obesity drugs, a market that has helped lift Lilly’s valuation and that investors treat as a multi-year growth engine. Novo said its once-daily Wegovy pill will start at $149 a month for self-paying patients, with
5 January 2026
·····
Merck stock in focus before Monday: Cidara deal deadline hits Jan. 6 as MRK sits near 52-week high

Merck stock in focus before Monday: Cidara deal deadline hits Jan. 6 as MRK sits near 52-week high

NEW YORK, Jan 4, 2026, 20:43 ET — Market closed Merck & Co shares closed up 1.1% on Friday at $106.45, leaving the stock within sight of a 52-week high ahead of Monday’s U.S. market reopen. MarketWatch The near-term focus is a tender offer — a takeover process where shareholders can sell stock directly for cash at a set price — tied to Merck’s planned purchase of Cidara Therapeutics. A Nasdaq corporate actions alert said the offer is scheduled to expire late Tuesday. NASDAQ Trader That timetable matters because it brings a catalyst into an otherwise light stretch for large-cap
5 January 2026
·····
INBS stock jumps on Syrma Johari deal: Intelligent Bio Solutions targets 40% cost cuts

INBS stock jumps on Syrma Johari deal: Intelligent Bio Solutions targets 40% cost cuts

NEW YORK, December 31, 2025, 5:04 PM ET — After-hours Shares of Intelligent Bio Solutions Inc more than doubled in Wednesday’s regular session as investors piled into the micro-cap medical technology stock on a fresh manufacturing update. The stock closed at $9.53, up $5.43 from Tuesday’s close of $4.10, and traded at $8.95 in after-hours dealings. The shares ranged from $5.62 to $12.94 on the day, giving the company a market value of about $9 million. Google The rally matters because manufacturing economics are a pressure point for small diagnostics and testing-device makers. Investors want proof that scaling hardware production
31 December 2025
····
Alignment Healthcare stock rises today despite new insider-sale filings, with ALHC near $20

Alignment Healthcare stock rises today despite new insider-sale filings, with ALHC near $20

NEW YORK, December 31, 2025, 14:50 ET — Regular session Alignment Healthcare, Inc. shares rose about 3.4% to $19.90 in mid-afternoon trading on Wednesday, after earlier touching $19.93 as the stock fluctuated between $18.83 and $19.93. The move came as investors weighed a cluster of insider-transaction disclosures that can shape sentiment in smaller healthcare names, especially in thin year-end markets. Liquidity has been patchy heading into the New Year holiday, a setup that can magnify price swings. “Profit-taking opportunities” tend to show up “when liquidity was low,” said Giuseppe Sette, co-founder and president of Reflexivity. Reuters A Form 4 filing
31 December 2025
····
UHS stock sinks today after CEO contract extension filing — here’s what moved the shares

UHS stock sinks today after CEO contract extension filing — here’s what moved the shares

NEW YORK, December 31, 2025, 13:23 ET — Regular session Universal Health Services, Inc. shares were down 2.75% at $218.87 in afternoon trading on Wednesday, extending losses as the hospital operator underperformed its peer group. The stock was down $6.19 from Tuesday’s close and touched $218.59 at the session low, with about 293,000 shares traded. The move matters now because governance and pay disclosures can become a catalyst in thin year-end trading, when investors reassess leadership incentives and stewardship. Hospital operators also enter 2026 facing close scrutiny on costs, staffing and reimbursement — areas where execution can swing margins quickly.
31 December 2025
····
Corcept Therapeutics (CORT) stock dives nearly 50% after FDA rejects relacorilant — what investors watch next

Corcept Therapeutics (CORT) stock dives nearly 50% after FDA rejects relacorilant — what investors watch next

NEW YORK, December 31, 2025, 13:58 ET — Regular session Shares of Corcept Therapeutics Incorporated (CORT.O) sank nearly 50% on Wednesday after the U.S. Food and Drug Administration issued a complete response letter for the company’s relacorilant application in hypertension secondary to hypercortisolism, also known as Cushing’s syndrome. The stock was down 49.7% at $35.31 in afternoon trading. Nasdaq The decision lands at a sensitive moment for investors who had been looking to relacorilant as the company’s next product story in Cushing’s beyond its marketed therapy. “FDA’s request for additional data may require additional trials, significantly dimming Corcept’s outlook in
31 December 2025
·····
Pfizer stock flat before the bell as report flags 2026 U.S. drug price hikes, including 15% Comirnaty rise

Pfizer stock flat before the bell as report flags 2026 U.S. drug price hikes, including 15% Comirnaty rise

NEW YORK, December 31, 2025, 08:51 ET — Premarket Pfizer Inc shares were little changed in premarket trading on Wednesday after a report showed the drugmaker is leading a new round of U.S. list-price increases for 2026. The stock was down about 0.02% at $24.99, after closing Tuesday at roughly $25.00. The issue matters now because drug pricing has returned to the front burner in Washington, with the Trump administration pressing manufacturers to rein in costs. Year-end is also when many companies set list-price changes that typically take effect in early January. For investors, higher list prices can support revenue
31 December 2025
·····
JNJ stock slips after hours as Johnson & Johnson closes $3.05B Halda Therapeutics deal

JNJ stock slips after hours as Johnson & Johnson closes $3.05B Halda Therapeutics deal

NEW YORK, December 30, 2025, 18:51 ET — After-hours Johnson & Johnson (JNJ) shares edged lower in after-hours trading on Tuesday after the healthcare conglomerate said it had completed its acquisition of Halda Therapeutics. The stock was down 0.3% at $206.91. The completion matters because investors are resetting portfolios into year-end with interest rates back in focus and dealmaking under a brighter spotlight. For J&J, the question is whether a new oncology platform can expand its pipeline without pressuring near-term profit metrics. The timing also pushes the spotlight onto management’s next set of targets. With the company set to talk
31 December 2025
····
Johnson & Johnson stock today: JNJ slips after $3.05B Halda cancer deal closes, Barclays lifts target

Johnson & Johnson stock today: JNJ slips after $3.05B Halda cancer deal closes, Barclays lifts target

NEW YORK, December 30, 2025, 12:44 ET — Regular session Johnson & Johnson shares edged lower on Tuesday after the company said it completed its $3.05 billion cash purchase of cancer-therapy developer Halda Therapeutics. The stock was down about 0.2% at $207.12 in midday trading. Executive vice president Jennifer Taubert called the closing a “strategic milestone” as J&J flagged about $0.20 of dilution to adjusted earnings per share — profit per share excluding certain one-time items — split between 2025 and 2026. Johnson & Johnson Investor Relations The closing gives J&J a new platform aimed at developing oral, targeted cancer
30 December 2025
····
Eli Lilly stock today: LLY inches up as weight-loss pill pricing, insider filing keep spotlight on obesity drugs

Eli Lilly stock today: LLY inches up as weight-loss pill pricing, insider filing keep spotlight on obesity drugs

NEW YORK, December 29, 2025, 17:45 ET — After-hours Shares of Eli Lilly and Company (LLY) were up 0.2% at $1,078.73 in after-hours trading on Monday. The stock traded between $1,074.80 and $1,085.12 and about 1.64 million shares had changed hands. The modest move masked a bigger debate underway in the obesity-drug trade: pricing and access. Investors are watching whether Lilly can widen uptake without giving away too much margin. Pills sit at the center of that calculus because they may lower barriers for patients who avoid injections. A shift toward out-of-pocket buying also changes who sets the rules —
29 December 2025
····
Eli Lilly Stock (LLY) Today: GLP‑1 Price Cuts, the Obesity Pill Race, and What Investors Are Watching Into 2026

Eli Lilly Stock (LLY) Today: GLP‑1 Price Cuts, the Obesity Pill Race, and What Investors Are Watching Into 2026

New York — Friday, December 26, 2025 (2:28 p.m. ET): Eli Lilly and Company (NYSE: LLY) is trading near $1,075 per share, essentially flat to slightly lower on the day in a thin, post‑Christmas U.S. session where the major indexes are hovering close to record levels. Reuters For investors, the timing matters: holiday trading often amplifies short‑term moves and can distort intraday signals. But Lilly is not a “holiday tape” stock—its valuation and momentum remain anchored to a handful of blockbuster catalysts in obesity and diabetes, plus a pipeline that’s becoming harder for competitors to match. Below is a market‑relevant,
26 December 2025
·····
AbbVie (ABBV) Stock News Today, Dec. 23, 2025: Beyond Botox Pipeline Push, Analyst Targets, and What to Watch Next

AbbVie (ABBV) Stock News Today, Dec. 23, 2025: Beyond Botox Pipeline Push, Analyst Targets, and What to Watch Next

AbbVie Inc. (NYSE: ABBV) stock traded mostly steady to slightly higher on Tuesday, Dec. 23, 2025, as investors balanced a holiday-shortened trading week with a fresh burst of company-specific pipeline headlines and ongoing debate about U.S. drug-pricing policy. As of Tuesday afternoon, ABBV changed hands around $228.62, up about 0.31% on the day, after trading in a $227.88–$230.77 range. What stands out on Dec. 23 is less about a single blockbuster “breaking” announcement and more about a cluster of signals—pipeline ambition in aesthetics and therapeutics, late-stage movement in eye care, and the ever-present question for long-term holders: how durable is
23 December 2025
·····
1 … 5 6 7 8 9 … 12

Stock Market Today

Halma share price: Friday’s lift sets up what investors watch next week

Halma share price: Friday’s lift sets up what investors watch next week

7 February 2026
Halma shares closed up 0.7% at 3,548 pence on Friday, valuing the group at about £13.4 billion. The Bank of England held rates at 3.75% in a split vote, keeping rate-cut speculation in focus. Halma’s next trading update is set for March 12. The FTSE 100 ended the week up 0.6%, lifted by bank stocks.
Diageo share price slips into the weekend as investors eye Feb. 25 results

Diageo share price slips into the weekend as investors eye Feb. 25 results

7 February 2026
Diageo shares closed down 1.48% at 1,760 pence on Friday, trailing a 0.59% gain in the FTSE 100. An updated analyst consensus points to a 2.0% fall in first-half organic net sales ahead of interim results due Feb. 25. Trading volume was light, and the stock remains over 22% below its 52-week high.
National Grid share price: what to know before London reopens after BoE signal

National Grid share price: what to know before London reopens after BoE signal

7 February 2026
National Grid shares closed at 1,285 pence in London on Friday, up 0.23%. The Bank of England held rates at 3.75% after a close vote, signaling possible cuts if inflation falls. National Grid announced a wireless power transmission study with Space Solar and marked five years of IFA2 interconnector operations. Its U.S. ADR ended at $88.06, up $1.17.
BAE Systems share price rises into weekend — what to watch before Monday’s London open

BAE Systems share price rises into weekend — what to watch before Monday’s London open

7 February 2026
BAE Systems shares closed up 1.2% at 1,879 pence on Friday, tracking gains in European defence stocks. The company’s market value stands near £54.8 billion. Investors await BAE’s full-year results on Feb. 18 for updates on cash returns and orders. GXO Logistics renewed and expanded its contract to support BAE’s Type 26 frigate program in Scotland.
Go toTop